{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:25:22Z","timestamp":1787772322709,"version":"build-2784847793"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical trials have been published regarding the anti-VEGF use in ROP, along with multiple other studies looking into the different agents, doses, techniques, and possible complications. Anti-VEGF therapies can be considered as a safe and effective option for managing ROP. More longitudinal randomized clinical trials are necessary to evaluate the preferred treatment agent, the appropriate dose, best follow-up protocol, and the long-term ocular and systemic outcomes following treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjopt.sjopt_12_22","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T06:27:54Z","timestamp":1716186474000},"page":"260-269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Anti-vascular endothelial growth factor therapy in retinopathy of prematurity"],"prefix":"10.4103","volume":"36","author":[{"given":"Asma K.","family":"Alzuabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola M.","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah N.","family":"Almousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan A.","family":"Abouammoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240830","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41372-021-01015-8","article-title":"80 Years of vision: Preventing blindness from retinopathy of prematurity","volume":"41","author":"Wood","year":"2021","journal-title":"J Perinatol"},{"key":"R2-5-20240830","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: Understanding retinopathy through ROP the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-5-20240830","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R4-5-20240830","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archopht.1988.01060130509025","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity","volume":"106","author":"Tasman","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R5-5-20240830","first-page":"311","article-title":"15-year outcomes following threshold retinopathy of prematurity: Final results from the multicenter trial of cryotherapy for retinopathy of prematurity","volume":"123","author":"Palmer","year":"2005","journal-title":"Arch Ophthalmol (Chicago, Ill 1960"},{"key":"R6-5-20240830","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/bjo.2006.098582","article-title":"The early treatment for retinopathy of prematurity study: Structural findings at age 2 years","volume":"90","author":"Good","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R7-5-20240830","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R8-5-20240830","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R9-5-20240830","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-5-20240830","first-page":"145","article-title":"Anti-VEGF for ROP and pediatric retinal diseases","volume":"7","author":"Wu","year":"2018","journal-title":"Asia Pac J Ophthalmol (Philadelphia, Pa"},{"key":"R11-5-20240830","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.preteyeres.2017.09.002","article-title":"Pathophysiology screening and treatment of ROP: A multi-disciplinary perspective","volume":"62","author":"Chan-Ling","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R12-5-20240830","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R13-5-20240830","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","volume":"32","author":"Stewart","year":"2012","journal-title":"Retina (Philadelphia, Pa"},{"key":"R14-5-20240830","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor \u2013 A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology (Rochester, Minn"},{"key":"R15-5-20240830","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R16-5-20240830","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2017.10.027","article-title":"Evolving concepts in the management of retinopathy of prematurity","volume":"186","author":"Sternberg","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R17-5-20240830","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R18-5-20240830","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R19-5-20240830","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R20-5-20240830","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina (Philadelphia, Pa"},{"key":"R21-5-20240830","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-5-20240830","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: Efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"R23-5-20240830","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/08820538.2015.1114847","article-title":"Role of VEGF inhibition in the treatment of retinopathy of prematurity","volume":"31","author":"Eldweik","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"R24-5-20240830","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R25-5-20240830","first-page":"e5","article-title":"What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model","volume":"1.1","author":"Stewart","year":"2011","journal-title":"Eye Reports [Online"},{"key":"R26-5-20240830","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","article-title":"Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity","volume":"67","author":"Vedantham","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R27-5-20240830","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-5-20240830","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","article-title":"The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm Res"},{"key":"R29-5-20240830","first-page":"37","article-title":"Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys","volume":"14","author":"Zhang","year":"2008","journal-title":"Mol Vis"},{"key":"R31-5-20240830","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R32-5-20240830","doi-asserted-by":"crossref","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"},{"key":"R33-5-20240830","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R34-5-20240830","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: What we know after 7 years","volume":"52","author":"Klufas","year":"2015","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R35-5-20240830","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjophthalmol-2016-308828","article-title":"The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: A systematic review","volume":"101","author":"Kandasamy","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R36-5-20240830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOP.0b013e32832925f9","article-title":"Antivascular endothelial growth factor for retinopathy of prematurity","volume":"21","author":"Mintz-Hittner","year":"2009","journal-title":"Curr Opin Pediatr"},{"key":"R37-5-20240830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"R38-5-20240830","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: A phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R39-5-20240830","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","article-title":"Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: A case series","volume":"102","author":"Hillier","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R40-5-20240830","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4103\/ijo.IJO_2115_18","article-title":"The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity","volume":"67","author":"Akdogan","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R41-5-20240830","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina (Philadelphia, Pa"},{"key":"R42-5-20240830","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina (Philadelphia, Pa"},{"key":"R43-5-20240830","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: A randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R44-5-20240830","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R45-5-20240830","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R46-5-20240830","doi-asserted-by":"crossref","first-page":"93.e1","DOI":"10.1016\/j.jaapos.2020.11.020","article-title":"Comparison of two different doses of intravitreal aflibercept in the treatment of retinopathy of prematurity","volume":"25","author":"Ekinci","year":"2021","journal-title":"J AAPOS"},{"key":"R47-5-20240830","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1167\/iovs.13-13397","article-title":"Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy","volume":"55","author":"Tokunaga","year":"2014","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R48-5-20240830","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.oret.2018.06.008","article-title":"Management of infantile and childhood retinopathies: Optimized pediatric pars plana vitrectomy sclerotomy nomogram","volume":"2","author":"Wright","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R49-5-20240830","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/IAE.0000000000001561","article-title":"Technique for infant intravitreal injection in treatment of retinopathy of prematurity","volume":"37","author":"Wright","year":"2017","journal-title":"Retina"},{"key":"R50-5-20240830","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/IAE.0000000000002172","article-title":"Report of safety of the use of a short 32G needle for intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity: A multicenter study","volume":"38","author":"Cernichiaro-Espinosa","year":"2018","journal-title":"Retina (Philadelphia, Pa"},{"key":"R51-5-20240830","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3928\/23258160-20200702-05","article-title":"SAFER-ROP: updated protocol for anti-VEGF injections for retinopathy of prematurity","volume":"51","author":"Beck","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R53-5-20240830","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: Timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R54-5-20240830","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"R55-5-20240830","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"R56-5-20240830","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: Report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology (Rochester, Minn"},{"key":"R57-5-20240830","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology (Rochester, Minn"},{"key":"R58-5-20240830","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: A 5 year follow up","volume":"109","author":"O'Keeffe","year":"2016","journal-title":"Irish Med J"},{"key":"R59-5-20240830","first-page":"e417","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol (Oxford, England"},{"key":"R60-5-20240830","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina (Philadelphia, Pa"},{"key":"R61-5-20240830","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond"},{"key":"R62-5-20240830","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"R63-5-20240830","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-020-00276-3","article-title":"Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors","volume":"7","author":"Bazvand","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R64-5-20240830","first-page":"136","article-title":"Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity","volume":"7","author":"Darwish","year":"2018","journal-title":"Asia Pac J Ophthalmol (Philadelphia, Pa"},{"key":"R65-5-20240830","first-page":"135","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"key":"R66-5-20240830","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: Refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R67-5-20240830","doi-asserted-by":"crossref","first-page":"e042384","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: A meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"key":"R68-5-20240830","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R69-5-20240830","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3928\/23258160-20160419-16","article-title":"Current practice patterns for treatment of retinopathy of prematurity","volume":"47","author":"Tawse","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R70-5-20240830","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"key":"R71-5-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R72-5-20240830","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"R73-5-20240830","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"R74-5-20240830","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"R75-5-20240830","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"R76-5-20240830","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J Perinatol"},{"key":"R77-5-20240830","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: A prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology (Rochester, Minn"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_12_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:38:48Z","timestamp":1787769528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_12_22"}},"subtitle":["An updated literature review"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/sjopt.sjopt_12_22","relation":{},"ISSN":["1319-4534"],"issn-type":[{"value":"1319-4534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}